BriaCell Therapeutics Corp. BCTX
Last close
3.44
2026-10-23
Market cap
$29.9M
2026-04-30 share count
52-week range
2.60 - 13.80
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-62.19
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $21.3M | $27.2M | $15.3M | $8.0M | $2.0M | — | — | — |
| SG&A | $5.9M | $6.2M | $7.9M | $7.3M | $5.0M | — | — | — |
| Total operating expenses | $27.2M | $33.3M | $23.3M | — | — | — | — | — |
| Operating income | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M | -$3.9M | — | — |
| Interest expense | $37.0K | — | — | $979 | $78.6K | — | — | — |
| Pre-tax income | $26.6M | $4.9M | $20.3M | -$26.8M | -$13.8M | — | — | — |
| Income tax | — | — | — | $0 | $0 | — | — | — |
| Net income | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M | -$4.0M | -$4.7M | — |
| EPS, basic | -62.19 | -43.68 | -1.30 | -1.73 | -3.06 | — | — | — |
| EPS, diluted | -62.19 | -43.68 | -1.30 | -1.73 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 423,114 | 109,699 | 15.6M | 15.5M | 4.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.5M | $862.1K | $21.3M | $41.0M | $57.3M | — | — | — |
| Short-term investments | $7.4M | — | — | — | — | — | — | — |
| Receivables | — | — | $18.9K | $24.1K | $12.6K | — | — | — |
| Total current assets | $19.9M | $3.7M | $26.9M | $42.3M | $57.8M | — | — | — |
| Property, plant and equipment | $296.8K | $388.2K | $2.5K | $2.5K | — | — | — | — |
| Other intangibles | $184.5K | $199.8K | $215.1K | $230.3K | $245.6K | — | — | — |
| Total assets | $21.6M | $5.9M | $27.2M | $42.6M | $58.0M | $522.3K | $444.7K | — |
| Total current liabilities | $4.0M | $7.5M | $1.8M | $941.1K | $556.8K | — | — | — |
| Retained earnings | -$111.8M | -$85.4M | -$80.7M | -$60.3M | -$29.1M | — | — | — |
| Total equity | $17.3M | -$2.7M | -$3.8M | $10.3M | $27.7M | -$2.7M | -$688.7K | $1.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M | — | — | — |
| Depreciation and amortisation | $91.4K | $68.6K | — | $15.3K | $15.3K | — | — | — |
| Stock-based compensation | $776.9K | $1.8M | $2.2M | $3.1M | $2.0M | — | — | — |
| Capital expenditure | — | $456.8K | — | — | — | — | — | — |
| Investing cash flow | -$7.6M | -$681.8K | — | — | — | — | — | — |
| Financing cash flow | $45.4M | $4.4M | $4.0M | -$3.7M | $65.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-25-018212.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$4.7M | -$4.0M | -$13.8M | -$26.8M | -$20.3M | -$4.8M | -$26.3M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |